Hydrogel News and Research

RSS

EndoChoice announces acquisition of Pathworks Anatomic Pathology Laboratory

EndoChoice, Inc. announced today that it has acquired Pathworks Anatomic Pathology Laboratory. Founded in 1989, Pathworks is a College of American Pathologists (CAP) accredited national reference laboratory located in Atlanta, GA. Robert Smith, MD, founder of the laboratory, will assume the Medical Director position of EndoChoice Pathology, a wholly-owned subsidiary of EndoChoice, Inc.

8 Apr 2010

MAP Pharmaceuticals initiates PD trial comparing LEVADEX to IV DHE

MAP Pharmaceuticals, Inc. today announced that the Company initiated a pharmacodynamics (PD) trial to compare the acute effect of LEVADEX™ orally inhaled migraine therapy to intravenous dihydroergotamine mesylate (IV DHE) and placebo on pulmonary artery pressure as measured by echocardiography.

8 Apr 2010

Oculus Innovative Sciences introduces Microcyn Dermatology HydroGel in the U.S.

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today commercially introduced the Microcyn Dermatology HydroGel for the U.S. professional healthcare market.

26 Mar 2010

Innovative tissue damage preventing cardiac scaffold awarded Rappaport Prize for biomedical research

Prof. Smadar Cohen, head of the University's Avram and Stella Goldstein-Goren Department of Biotechnology Engineering, has been awarded the prestigious Rappaport Prize for Excellence in Biomedical Research, an award totaling $100,000. The prize, given by Israel's Rappaport Foundation, is presented annually to a researcher whose research has either significantly advanced or has the potential to significantly advance any medical or biomedical field.

20 Mar 2010

Babies born with severe cleft palates: Promising breakthrough without complex surgery

Scientists working on a treatment for babies born with cleft palates have made a promising breakthrough and the first clinical trials are planned for early next year. Clefts are the most common birth defect in Britain, with one in every 700 babies affected; currently in severe cases radical surgery is required to correct the problem, and in addition future complications can occur as the child grows into an adult.

18 Mar 2010

HyperBranch Medical Technology's surgical sealants to be marketed under new name – Adherus Surgical Sealants

HyperBranch Medical Technology, Inc. announced today that it will begin to market their surgical sealants under a new product identity – Adherus Surgical Sealants.

11 Mar 2010

FDA clears Oculus Innovative Sciences' Microcyn Skin and Wound HydroGel

Oculus Innovative Sciences, Inc., a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

10 Mar 2010

Replication Medical receives CE mark for GelFix Posterior Spinal Distraction implant

Replication Medical, Inc., a developer of proprietary, hydrogel based products for the spine and other surgical applications, announced today that it has received a CE mark for its GelFix Posterior Spinal Distraction implant. A CE mark is the quality assurance certification requirement recognized by members of the European Union for sales into those countries.

8 Mar 2010

MiMedx Group's HydroFix Spine Shield device receives CE Mark

MiMedx Group, Inc. announced today that the Company received the CE Mark for its HydroFix™ Spine Shield device and was certified for design, development, and production of post-surgical adhesion inhibiting barriers.

1 Mar 2010

MiMedx Group completes corporate and technology branding initiative

MiMedx Group, Inc. announced today that it has completed its corporate and technology branding initiative. In concert with its branding initiative, the Company also announced that it has recently launched an updated website.

25 Feb 2010

CryoLife discloses financial results for fourth-quarter and full-year 2009

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that revenues for the fourth quarter of 2009 increased 12 percent to a quarterly record of $28.6 million compared to $25.5 million for the fourth quarter of 2008. This was the 12th consecutive quarter of profitability for the Company.

18 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

Beer may help prevent osteoporosis

A new study suggests that beer is a significant source of dietary silicon, a key ingredient for increasing bone mineral density. Researchers from the Department of Food Science & Technology at the University of California, Davis studied commercial beer production to determine the relationship between beer production methods and the resulting silicon content, concluding that beer is a rich source of dietary silicon. Details of this study are available in the February issue of the Journal of the Science of Food and Agriculture, published by Wiley-Blackwell on behalf of the Society of Chemical Industry.

8 Feb 2010

Neomend completes $30M Series D funding round

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced today it has completed a funding round of $30 million, with Clarus Ventures, LLC investing $17 million.

28 Jan 2010

Neomend receives premarket approval from FDA for ProGEL Pleural Air Leak Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the company’s ProGEL™ Pleural Air Leak Sealant.

20 Jan 2010

MiMedx Group launches its Paradis Vaso Shield vessel cover product

MiMedx Group, Inc. announced today that it has officially launched its first product, Paradis Vaso Shield(TM). In April 2009, The Food and Drug Administration cleared the Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process.

24 Dec 2009

LecTec issues open letter to shareholders on company’s current developments

LecTec Corporation announced today that it has issued the following open letter from Judd Berlin, the Chief Executive Officer of LecTec, to its shareholders regarding current developments at the Company:

23 Dec 2009

Monitoring blood glucose levels with contact lenses may soon be a reality for diabetes patients

Diabetics may soon be able to wear contact lenses that continuously alert them to variations in their glucose levels by changing colours - replacing the need to routinely draw blood throughout the day.

22 Dec 2009

Researchers use hydrogels to induce significant vasculature growth in areas of damaged tissue

Regenerative medicine therapies often require the growth of functional, stable blood vessels at the site of an injury. Using synthetic polymers called hydrogels, researchers at the Georgia Institute of Technology have been able to induce significant vasculature growth in areas of damaged tissue.